Analytical and Real‐World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population
The Prostate · 2025
DOI: 10.1002/pros.24894 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yuki Miura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Image-Guided Biopsy, Prostate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This work was supported by the Japan Society for the Promotion of Science KAKENHI (Grant No. 24K12501)..
Abstract (Originalsprache)
Background
The α2,3‐sialyl N ‐glycosylated free prostate‐specific antigen ratio (S2,3PSA%) was approved in Japan as a prostate cancer (PCa) diagnostic test. We evaluated the analytical characterization and real‐world diagnostic performance of S2,3PSA%.
Methods
The precision testing, dilution linearity, measurement sensitivity, preanalytical stability, and interferences of S2,3PSA, α2,6‐sialyl N ‐glycosylated free PSA (S2,6PSA), and S2,3PSA% were performed. The diagnostic accuracy detecting PCa of S2,3PSA% was prospectively evaluated in 253 men (Cohort 1, vs. PI‐RADS) and in 145 men (Cohort 2, vs. PI‐RADS, prostate health index , phi ) who scheduled MRI‐targeted biopsy by area under the receiver operating characteristics curve (AUC).
Results
The precision of the S2,3PSA, S2,6PSA, and S2,3PSA% were all < 3.4% coefficient of variation. The dilution linearity of S2,3PSA had a correlation coefficient of 0.9949–0.9987. The detection limit of S2,3PSA and S2,6PSA was 0.044 and 0.029 ng/mL, respectively. Serum S2,3PSA and S2,6PSA concentrations were stable at 6°C for 24 h and −20°C for 90 days, while S2,3PSA% was unchanged at 6°C and −20°C for 90 days or under five freeze–thaw cycles. Serum S2,3PSA and S2,3PSA% were not affected by any interferences and drugs. In Cohort 1, AUC of S2,3PSA% (0.776, 95% CI 0.719–0.832) detecting PCa was comparable to that of PI‐RADS (0.746, 0.685–0.807, p = 0.7996). In Cohort 2, AUC of S2,3PSA% detecting PCa (0.837, 0.774–0.901) was comparable to PI‐RADS (0.779, 0.703–0.854, p = 0.3037), and phi (0.867, 0.809–0.926, p = 0.3000).
Conclusions
Analytical characteristics of S2,3PSA% perform well and the diagnostic performance of S2,3PSA% was comparable to phi and MRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Glycotechnology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Medical Systems Research & Development Center, Fujifilm Corporation, Tokyo, Japan.
- Clinical Laboratory Department, Hirosaki University Hospital, Hirosaki, Japan.
- Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
ORCID-Profile: Tohru Yoneyama, Naoki Fujita, Shingo Hatakeyama
Förderung
- This work was supported by the Japan Society for the Promotion of Science KAKENHI (Grant No. 24K12501).
Zitieren
APA
Miura, Y., Yoneyama, T., Yamamoto, H., Suzuki, H., Otsubo, T., Fujita, E., Tsushima, F., Goto, S., Okamoto, T., Fujita, N., Ishiyama, M., Yoshizawa, T., Kakeda, S., Hatakeyama, S., & Ohyama, C. (2025). Analytical and Real‐World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population. The Prostate. https://doi.org/10.1002/pros.24894
Vancouver
Miura Y, Yoneyama T, Yamamoto H, Suzuki H, Otsubo T, Fujita E, et al. Analytical and Real‐World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population. The Prostate. 2025. doi:10.1002/pros.24894
BibTeX
@article{Miura2025,
author = {Miura, Yuki and Yoneyama, Tohru and Yamamoto, Hayato and Suzuki, Hiromu and Otsubo, Takuma and Fujita, Eriko and Tsushima, Fumiyasu and Goto, Shintaro and Okamoto, Teppei and Fujita, Naoki and Ishiyama, Masahiro and Yoshizawa, Tadashi and Kakeda, Shingo and Hatakeyama, Shingo and Ohyama, Chikara},
title = {Analytical and Real‐World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24894}
}
EUVIMED